Bench-to-bedside review: The gut as an endocrine organ in the critically ill

Critical Care

Volumn 14, Issue 5, 2010, Pages

  Deane, Adam ^a,b,c   Chapman, Marianne J ^a,b,c   Fraser, Robert J L ^c,d,e   Horowitz, Michael ^c,e  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; ERYTHROMYCIN; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; INSULIN; MOTILIN; PEPTIDE YY; TEDUGLUTIDE;

APPETITE; CRITICALLY ILL PATIENT; ENZYME RELEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; GLUCAGON RELEASE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMMUNE FUNCTION TEST; INSULIN RELEASE; INTENSIVE CARE; INTESTINE; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE TRANSIT TIME; LOWER ESOPHAGUS SPHINCTER; MOTOR ACTIVITY; NONHUMAN; PANCREAS ISLET CELL; PARENTERAL NUTRITION; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; WEIGHT REDUCTION; ANIMAL; CRITICAL ILLNESS; DRUG EFFECT; ENDOCRINE SYSTEM; GLUCOSE BLOOD LEVEL; HOSPITAL INFORMATION SYSTEM; INTESTINE ABSORPTION; METABOLISM; PHYSIOLOGY; SECRETION;

ANIMALS; BLOOD GLUCOSE; CHOLECYSTOKININ; CRITICAL ILLNESS; ENDOCRINE SYSTEM; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; PEPTIDE YY; POINT-OF-CARE SYSTEMS;

EID: 79851508165     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9039     Document Type: Review

References (102)

1. Baynes KC, Dhillo WS, Bloom SR. Regulation of food intake by gastrointestinal hormones. Curr Opin Gastroenterol 2006, 22:626-631. 10.1097/01.mog.0000245537.43142.63, 17053440.
2. Thompson JS. The intestinal response to critical illness. Am J Gastroenterol 1995, 90:190-200.
3. Nguyen NQ, Ng MP, Chapman M, Fraser RJ, Holloway RH. The impact of admission diagnosis on gastric emptying in critically ill patients. Crit Care 2007, 11:R16. 2151889, 17288616, 10.1186/cc5685.
4. Nind G, Chen WH, Protheroe R, Iwakiri K, Fraser R, Young R, Chapman M, Nguyen N, Sifrim D, Rigda R, Holloway RH. Mechanisms of gastroesophageal reflux in critically ill mechanically ventilated patients. Gastroenterology 2005, 128:600-606. 10.1053/j.gastro.2004.12.034, 15765395.
5. Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996, 22:1339-1344. 10.1007/BF01709548, 8986483.
6. Deane AM, Fraser RJ, Chapman MJ. Prokinetic drugs for feed intolerance in critical illness: current and potential therapies. Crit Care Resusc 2009, 11:132-143.
7. Nguyen NQ, Fraser RJ, Chapman M, Bryant LK, Holloway RH, Vozzo R, Feinle-Bisset C. Proximal gastric response to small intestinal nutrients is abnormal in mechanically ventilated critically ill patients. World J Gastroenterol 2006, 12:4383-4388.
8. Chapman M, Fraser R, Vozzo R, Bryant L, Tam W, Nguyen N, Zacharakis B, Butler R, Davidson G, Horowitz M. Antro-pyloro-duodenal motor responses to gastric and duodenal nutrient in critically ill patients. Gut 2005, 54:1384-1390. 1774690, 15923669, 10.1136/gut.2005.065672.
9. Chapman MJ, Fraser RJ, Bryant LK, Vozzo R, Nguyen NQ, Tam W, Zacharakis B, Davidson G, Butler R, Horowitz M. Gastric emptying and the organization of antro-duodenal pressures in the critically ill. Neurogastroenterol Motil 2008, 20:27-35. 10.1111/j.1365-2982.2007.00984.x, 18069967.
10. Rauch S, Krueger K, Turan A, Roewer N, Sessler DI. Determining small intestinal transit time and pathomorphology incritically ill patients using video capsule technology. Intensive Care Med 2009, 35:1054-1059. 10.1007/s00134-009-1415-6, 19183950.
11. Johnston JD, Harvey CJ, Menzies IS, Treacher DF. Gastrointestinal permeability and absorptive capacity in sepsis. Crit Care Med 1996, 24:1144-1149. 10.1097/00003246-199607000-00013, 8674326.
12. Chapman MJ, Fraser RJ, Matthews G, Russo A, Bellon M, Besanko LK, Jones KL, Butler R, Chatterton B, Horowitz M. Glucose absorption and gastric emptying in critical illness. Crit Care 2009, 13:R140. 2750198, 19712450, 10.1186/cc8021.
13. Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol 2003, 17:397-425. 10.1016/S1521-6918(03)00024-6, 12763504.
14. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perencevich EN. Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations. Crit Care Med 2005, 33:2772-2777. 10.1097/01.CCM.0000189741.44071.25, 16352959.
15. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. 10.1056/NEJMoa011300, 11794168.
16. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354:449-461. 10.1056/NEJMoa052521, 16452557.
17. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297. 10.1056/NEJMoa0810625, 19318384.
18. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006, 105:244-252. 10.1097/00000542-200608000-00006, 16871057.
19. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001, 86:5992-5995. 10.1210/jc.86.12.5992, 11739476.
20. Parker BA, Doran S, Wishart J, Horowitz M, Chapman IM. Effects of small intestinal and gastric glucose administration on the suppression of plasma ghrelin concentrations in healthy older men and women. Clin Endocrinol (Oxf) 2005, 62:539-546. 10.1111/j.1365-2265.2005.02254.x, 15853822.
21. Little TJ, Doran S, Meyer JH, Smout AJ, O'Donovan DG, Wu KL, Jones KL, Wishart J, Rayner CK, Horowitz M, Feinle-Bisset C. The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. Am J Physiol Endocrinol Metab 2006, 291:E647-E655. 16684852, 10.1152/ajprenal.00475.2005.
22. Cukier K, Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Horowitz M, Feinle-Bisset C. Effect of small intestinal glucose load on plasma ghrelin in healthy men. Am J Physiol Regul Integr Comp Physiol 2008, 295:R459-R462.
23. Misra M, Miller KK, Herzog DB, Ramaswamy K, Aggarwal A, Almazan C, Neubauer G, Breu J, Klibanski A. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls. J Clin Endocrinol Metab 2004, 89:1605-1612. 10.1210/jc.2003-031861, 15070919.
24. Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev 2005, 57:541-546. 10.1124/pr.57.4.1, 16382107.
25. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008, 149:601-611. 2757071, 18981485.
26. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005, 22:847-853. 10.1111/j.1365-2036.2005.02658.x, 16225494.
27. Murray CD, Martin NM, Patterson M, Taylor SA, Ghatei MA, Kamm MA, Johnston C, Bloom SR, Emmanuel AV. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005, 54:1693-1698. 1774813, 16085693, 10.1136/gut.2005.069088.
28. De Winter BY, De Man JG, Seerden TC, Depoortere I, Herman AG, Peeters TL, Pelckmans PA. Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Neurogastroenterol Motil 2004, 16:439-446. 10.1111/j.1365-2982.2004.00564.x, 15305999.
29. Ejskjaer N, Vestergaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L, Kosutic G. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009, 29:1179-1187. 10.1111/j.1365-2036.2009.03986.x, 19298585.
30. Venkova K, Fraser G, Hoveyda HR, Greenwood-Van Meerveld B. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci 2007, 52:2241-2248. 10.1007/s10620-007-9783-7, 17436082.
31. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001, 86:5083-5086. 10.1210/jc.86.10.5083, 11600590.
32. Nematy M, O'Flynn JE, Wandrag L, Brynes AE, Brett SJ, Patterson M, Ghatei MA, Bloom SR, Frost GS. Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study. Crit Care 2006, 10:R10. 1550795, 16420657, 10.1186/cc3957.
33. Nematy M, Brynes AE, Hornick PI, Patterson M, Ghatei MA, Bloom SR, Brett SJ, Frost GS. Postprandial ghrelin suppression is exaggerated following major surgery; implications for nutritional recovery. Nutr Metab (Lond) 2007, 4:20. 2173899, 17922905, 10.1186/1743-7075-4-20.
34. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, Kangawa K. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005, 128:1187-1193. 10.1378/chest.128.3.1187, 16162705.
35. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004, 110:3674-3679. 10.1161/01.CIR.0000149746.62908.BB, 15569841.
36. Takeshita E, Matsuura B, Dong M, Miller LJ, Matsui H, Onji M. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol 2006, 41:223-230. 10.1007/s00535-005-1739-0, 16699856.
37. Vantrappen G, Janssens J, Peeters TL, Bloom SR, Christofides ND, Hellemans J. Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci 1979, 24:497-500. 10.1007/BF01489315, 456236.
38. Peeters TL, Muls E, Janssens J, Urbain JL, Bex M, Van Cutsem E, Depoortere I, De Roo M, Vantrappen G, Bouillon R. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Gastroenterology 1992, 102:97-101.
39. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990, 322:1028-1031. 10.1056/NEJM199004123221502, 2320062.
40. Fraser R, Shearer T, Fuller J, Horowitz M, Dent J. Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric, and duodenal motility. Gastroenterology 1992, 103:114-119.
41. Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999, 22:339-344. 10.2337/diacare.22.2.339, 10333955.
42. Thielemans L, Depoortere I, Perret J, Robberecht P, Liu Y, Thijs T, Carreras C, Burgeon E, Peeters TL. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 2005, 313:1397-1405. 10.1124/jpet.104.081497, 15764739.
43. Chaussade S, Michopoulos S, Sogni P, Guerre J, Couturier D. Motilin agonist erythromycin increases human lower esophageal sphincter pressure by stimulation of cholinergic nerves. Dig Dis Sci 1994, 39:381-384. 10.1007/BF02090212, 8313822.
44. Edelbroek MA, Horowitz M, Wishart JM, Akkermans LM. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects. J Nucl Med 1993, 34:582-588.
45. Landry C, Vidon N, Sogni P, Nepveux P, Chaumeil JC, Chauvin JP, Couturier D, Chaussade S. Effects of erythromycin on gastric emptying, duodeno-caecal transit time, gastric and biliopancreatic secretion during continuous gastric infusion of a liquid diet in healthy volunteers. Eur J Gastroenterol Hepatol 1995, 7:797-802.
46. Nguyen NQ, Chapman MJ, Fraser RJ, Bryant LK, Holloway RH. Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. Crit Care Med 2007, 35:483-489. 10.1097/01.CCM.0000253410.36492.E9, 17205032.
47. Maclaren R, Kiser TH, Fish DN, Wischmeyer PE. Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. J Parenter Enteral Nutr 2008, 32:412-419.
48. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, Horowitz M, Feinle-Bisset C. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007, 293:E743-E753. 10.1152/ajpendo.00159.2007, 17609258.
49. Beglinger C, Degen L, Matzinger D, D'Amato M, Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1149-R1154.
50. Clave P, Gonzalez A, Moreno A, Lopez R, Farre A, Cusso X, D'Amato M, Azpiroz F, Lluis F. Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 1998, 115:597-604. 10.1016/S0016-5085(98)70139-8, 9721157.
51. Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A, Stalder GA, Rovati L. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991, 101:503-511.
52. Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, D'Amato M, Crelier G, Boesiger P, Fried M. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997, 41:500-504. 1891533, 9391249, 10.1136/gut.41.4.500.
53. Hildebrand P, Beglinger C, Gyr K, Jansen JB, Rovati LC, Zuercher M, Lamers CB, Setnikar I, Stalder GA. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 1990, 85:640-646. 296477, 2312719, 10.1172/JCI114486.
54. Nguyen NQ, Fraser RJ, Chapman MJ, Bryant LK, Holloway RH, Vozzo R, Wishart J, Feinle-Bisset C, Horowitz M. Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations. Crit Care Med 2007, 35:82-88. 10.1097/01.CCM.0000250317.10791.6C, 17095943.
55. Nguyen NQ, Fraser RJ, Bryant LK, Chapman MJ, Wishart J, Holloway RH, Butler R, Horowitz M. The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care 2007, 11:R132. 2246231, 18154642, 10.1186/cc6205.
56. MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JB, Horowitz M, Chapman IM. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001, 86:5830-5837. 10.1210/jc.86.12.5830, 11739447.
57. Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2000, 2:99-103. 10.1046/j.1463-1326.2000.00070.x, 11220530.
58. Nguyen NQ, Fraser RJ, Bryant LK, Burgstad C, Chapman MJ, Bellon M, Wishart J, Holloway RH, Horowitz M. The impact of delaying enteral feeding on gastric emptying, plasma cholecystokinin, and peptide YY concentrations in critically ill patients. Crit Care Med 2008, 36:1469-1474. 10.1097/CCM.0b013e31816fc457, 18434906.
59. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985, 89:1070-1077.
60. Lin HC, Chey WY, Zhao X. Release of distal gut peptide YY (PYY) by fat in proximal gut depends on CCK. Peptides 2000, 21:1561-1563. 10.1016/S0196-9781(00)00312-0, 11068105.
61. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987, 28:166-170. 1432980, 3557189, 10.1136/gut.28.2.166.
62. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003, 349:941-948. 10.1056/NEJMoa030204, 12954742.
63. Zamir O, Hasselgren PO, Higashiguchi T, Frederick JA, Fischer JE. Effect of sepsis or cytokine administration on release of gut peptides. Am J Surg 1992, 163:181-184. discussion 184-185, 10.1016/0002-9610(92)90273-T, 1733367.
64. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967, 46:1954-1962. 292948, 6074000, 10.1172/JCI105685.
65. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996, 97:92-103. 507066, 8550855, 10.1172/JCI118411.
66. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antropyloroduodenal motility in humans. Gut 2006, 55:243-251. 1856508, 15985560, 10.1136/gut.2004.059741.
67. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999, 48:86-93. 10.2337/diabetes.48.1.86, 9892226.
68. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, Horowitz M. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95:215-221. 10.1210/jc.2009-1503, 19892837.
69. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2:1300-1304. 10.1016/S0140-6736(87)91194-9, 2890903.
70. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307. 330027, 8423228, 10.1172/JCI116186.
71. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counter regulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246. 10.1210/jc.87.3.1239, 11889194.
72. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005, 54:2212-2218. 10.2337/diabetes.54.7.2212, 15983224.
73. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998, 102:764-774. 508939, 9710445, 10.1172/JCI942.
74. Hellstrom PM, Naslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008, 20:649-659. 10.1111/j.1365-2982.2007.01079.x, 18298441.
75. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961. 10.1161/01.CIR.0000139339.85840.DD, 15313949.
76. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699. 10.1016/j.cardfail.2006.08.211, 17174230.
77. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118:89-97. 10.1016/j.regpep.2003.11.003, 14759561.
78. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32:848-851. 10.1097/01.CCM.0000114811.60629.B5, 15090972.
79. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100:824-829. 10.1016/j.amjcard.2007.05.022, 17719327.
80. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102:646-647. 10.1016/j.amjcard.2008.06.029, 18721530.
81. Deane AM, Chapman MJ, Fraser RJ, Burgstad C, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo controlled cross over study. Crit Care 2009, 13:R67. 2717426, 19439067, 10.1186/cc7874.
82. Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010, 38:1261-1269.
83. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol 2006, 290:E550-E559.
84. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973, 37:826-828. 10.1210/jcem-37-5-826, 4749457.
85. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 2002, 107:1-13. 10.1016/S0167-0115(02)00039-3, 12137960.
86. Layon AJ, Florete OG, Day AL, Kilroy RA, James PB, McGuigan JE. The effect of duodenojejunal alimentation on gastric pH and hormones in intensive care unit patients. Chest 1991, 99:695-702. 10.1378/chest.99.3.695, 1899823.
87. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999, 117:99-105. 10.1016/S0016-5085(99)70555-X, 10381915.
88. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007, 293:E460-E465. 10.1152/ajpendo.00149.2007, 17652153.
89. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130:44-54. 10.1053/j.gastro.2005.10.004, 16401467.
90. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997, 273(1 Pt 1):E77-E84.
91. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, Schmidt M, Holst JJ, Hartmann B, Sangild PT. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G1249-G1256.
92. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001, 120:806-815. 10.1053/gast.2001.22555, 11231933.
93. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005, 54:1224-1231. 1774653, 16099790, 10.1136/gut.2004.061440.
94. Niederau C, Grendell JH. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists. Digestion 1999, 60(Suppl 1):69-74. 10.1159/000051458, 10026436.
95. Shiratori K, Takeuchi T, Satake K, Matsuno S. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Pancreas 2002, 25:e1-e5. 10.1097/00006676-200207000-00003, 12131781.
96. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999, 341:785-792. 10.1056/NEJM199909093411102, 10477776.
97. Doig GS, Simpson F, Finfer S, Delaney A, Davies AR, Mitchell I, Dobb G. Effect of evidence-based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. JAMA 2008, 300:2731-2741. 10.1001/jama.2008.826, 19088351.
98. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and betacell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830. 10.1016/S0140-6736(02)07952-7, 11897280.
99. Mecott GA, Herndon DN, Kulp GA, Brooks N, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG. The use of exenatide in severely burned pediatric patients. Critical Care 2010, 14:R153. 10.1186/cc9222, 20701787.
100. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001, 50:2497-2504. 10.2337/diabetes.50.11.2497, 11679427.
101. Kouris GJ, Liu Q, Rossi H, Djuricin G, Gattuso P, Nathan C, Weinstein RA, Prinz RA. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001, 181:571-575. 10.1016/S0002-9610(01)00635-3, 11513789.
102. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659. 10.1016/S0140-6736(08)60207-X, 18279948.